Deficiencies can occur with medical conditions such as atrophic gastritis (which causes thinning of the stomach lining), pernicious anaemia, Crohns disease, celiac disease, lupus, or other immune system disorders and certain medications
UK patients should understand that: Available evidence is largely from Phase 2 studies with relatively short follow-up periods Long-term cardiovascular outcome data are not yet available for either agent Phase 3 trials are ongoing, and results will inform future regulatory submissions to the MHRA UK patients interested in accessing these treatments through clinical trials may wish to consult the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov for current recruitment opportunities
6, revealed a compelling narrative
adults struggle with insulin resistance , yet men often face unique challenges in finding effective treatment solutions that address their specific metabolic needs
Planning ahead protects both your medication and your treatment progress
Recognition and management of poisoning with beta-adrenergic blocking agents